Initial results from an ECOG-ACRIN and Caris Life Sciences collaboration show AI-driven multimodal models can more accurately predict recurrence risk in early-stage breast cancer.
Key Details
- 1Collaboration leverages ECOG-ACRIN's clinical trial data and Caris' molecular profiling and imaging AI platforms.
- 2Over 4,000 TAILORx trial patient cases used to train and validate new multimodal deep learning models.
- 3Models integrate histopathologic slide imaging, clinical, and expanded gene expression data.
- 4AI models outperformed established recurrence risk assessment methods, especially for late recurrence (after 5 years).
- 5Potential shown for a scalable, cost-effective diagnostic test based on routine histology and clinical data rather than solely on genomic assays.
- 6Results presented at the 2023 San Antonio Breast Cancer Symposium.
Why It Matters
The study demonstrates unprecedented large-scale integration of imaging, molecular, and clinical data for recurrence prognostication, charting a path toward more personalized and precise breast cancer management. Imaging AI's role in such multimodal frameworks signifies a promising advance for the development of new diagnostic tools in oncologic pathology.
Source
EurekAlert
Related News
•EurekAlert
AI and Advanced Microscopy Unveil Cell's Exocytosis Nanomachine
Researchers have discovered the ExHOS nanomachine responsible for constitutive exocytosis using advanced microscopy and AI-enhanced image analysis.
•EurekAlert
Physical Activity Linked to Breast Tissue Biomarkers in Teens
A study links adolescent recreational physical activity to changes in breast tissue composition and stress biomarkers, potentially impacting future breast cancer risk.
•EurekAlert
Deep Learning AI Outperforms Clinic Prognostics for Colorectal Cancer Recurrence
A new deep learning model using histopathology images identifies recurrence risk in stage II colorectal cancer more effectively than standard clinical predictors.